12 citations
,
May 2016 in “British Journal of Dermatology” A 6-year-old boy's skin condition improved after stopping a specific treatment and starting new medications.
January 2025 in “Geneesmiddelenbulletin” Baricitinib is effective and safe for treating severe alopecia areata with ongoing use.
June 2025 in “bioRxiv (Cold Spring Harbor Laboratory)” In alopecia areata, certain immune cells increase and express a protein linked to immune activation.
227 citations
,
April 2023 in “The Lancet” Ritlecitinib effectively treats alopecia areata and is well-tolerated.
October 2025 in “Dermatology and Therapy” Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
October 2024 in “Clinical Cosmetic and Investigational Dermatology” Brevilin-A is a safe and effective treatment for mild to moderate alopecia areata in children.
42 citations
,
November 2018 in “Archives of dermatological research” Apremilast was not effective in treating moderate-to-severe alopecia areata.
1 citations
,
August 2023 in “JAMA Dermatology” Increasing the dose of baricitinib to 4 mg helps more patients with severe alopecia areata regrow hair.
37 citations
,
October 2017 in “Clinical and Experimental Dermatology” Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.
141 citations
,
February 2005 in “Journal of the American Academy of Dermatology” Oral prednisolone helps hair regrowth in alopecia areata.
June 2023 in “Journal of Burn Care & Research” Using both bone marrow concentrate and platelet-rich plasma together improves skin wound healing in mice.
18 citations
,
December 2015 in “PubMed” Intralesional triamcinolone is more effective than topical betamethasone for treating localized alopecia areata.
3 citations
,
January 2025 in “Journal of Natural Products” Calancardin B may help reduce inflammation in immune cells.
2 citations
,
March 2025 in “International Journal of Dermatology” Tralokinumab successfully treated alopecia areata in a patient with atopic dermatitis.
December 2024 in “PubMed” 1 citations
,
October 2025 in “International Journal of Dermatology” Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.
September 2024 in “Skin Appendage Disorders” Tofacitinib helped a woman regrow her hair without relapses after other treatments failed.
February 2023 in “Reactions Weekly”
January 2024 in “Dermatologic therapy” Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.
March 2026 in “Folia Histochemica et Cytobiologica” LTBP1 is a key regulator in diseases and a potential target for new treatments.
2 citations
,
November 2021 in “ACG Case Reports Journal” Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.
September 2022 in “Plastic and Reconstructive Surgery” Baricitinib helps with severe hair loss, negative-pressure therapy lowers hernia recurrence, tranexamic acid reduces bleeding, robot-assisted breast surgery may improve outcomes, and acellular dermal matrix could decrease breast reconstruction complications.
1 citations
,
January 2021 in “Journal of clinical and diagnostic research” Using Calcipotriol with Clobetasol is more effective for treating Alopecia Areata than using Clobetasol alone.
June 2025 in “Preprints.org” Baricitinib improves alopecia areata and may help psoriasis but might not be ideal for psoriatic arthritis.
January 2023 in “Figshare” Triple therapy with clobetasol, hydroxychloroquine, and N-acetylcysteine is recommended for better outcomes in treating lichen planopilaris.
March 2026 in “Journal of Veterinary and Animal Sciences” Supplements improved calves' haircoat condition.
2 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Baricitinib is a safe and effective treatment for severe alopecia areata.
2 citations
,
April 2017 in “Journal of Investigative Dermatology” Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.
January 2026 in “Dermatology Reports” Upadacitinib improved symptoms and hair regrowth in a teen with multiple autoimmune conditions.
3 citations
,
June 2025 in “Archives of Dermatological Research” Biologics and JAK inhibitors may improve treatment for scarring alopecias.